Prediction of prognostic signatures in triple-negative breast cancer based on the differential expression analysis via NanoString nCounter immune panel

• Published in: BMC cancer Vol. 20; no. 1; pp. 1052 - 13
• Main Authors: Lim, Gyeong Back, Kim, Young-Ae, Seo, Jeong-Han, Lee, Hee Jin, Gong, Gyungyub, Park, Sung Hee
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 02.11.2020; BioMed Central; BMC
• Subjects: Accuracy; Biological markers; Biomarkers; Biomarkers, Tumor - genetics; Biopsy; Breast cancer; Cancer therapies; Care and treatment; Chemotherapy; Data analysis; Datasets; Diagnosis; Differential expression; ErbB-2 protein; Extracellular Matrix Proteins - genetics; Feature selection; Female; Gene expression; Gene Expression Profiling - instrumentation; Gene Expression Profiling - methods; Gene Expression Regulation, Neoplastic; Genetic aspects; Health aspects; Humans; Identification and classification; Immune response; Immunity; Immunology; Medical prognosis; Models, Genetic; NanoString nCounter immune panel; Pathological complete response; Prediction models; Progesterone; Prognosis; Prognostic marker; Proportional Hazards Models; Receptor, Endothelin B - genetics; Receptors, IgE - genetics; Relapse; Survival; Survival Analysis; Transforming Growth Factor beta - genetics; Triple negative breast cancer; Triple Negative Breast Neoplasms - genetics; Triple Negative Breast Neoplasms - mortality; Tumors; South Korea; Relapse; NanoString nCounter immune panel; Prediction model; Pathological complete response; Differential expression; Prognostic marker; Triple negative breast cancer; Random Forest

Triple-Negative Breast Cancer (TNBC) is an aggressive and complex subtype of breast cancer. The current biomarkers used in the context of breast cancer treatment are highly dependent on the targeting of oestrogen receptor, progesterone receptor, or HER2, resulting in treatment failure and disease re...